News
FDA aims for Tlando decision for testosterone replacement therapy in week of 7 December 2020.- Lipocine
Lipocine Inc. announced that the FDA has informed the Company that it is continuing to work towards taking action on the Tlando New Drug Application ("NDA") for testosterone replacement therapy during the week of December 7, 2020. However, the Company cannot assure that the FDA will act in that time frame.
Condition: Testosterone Deficiency
Type: drug